Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 22,541 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Conditions
Pregnant Women, Prenatal Care
Interventions
Not listed
Lead sponsor
Verinata Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Fort Collins, Colorado + 8 more
Conditions
Post-traumatic Stress Disorder, Insomnia
Interventions
pimavanserin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Severe Aplastic Anemia (SAA)
Interventions
REGN7257
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Cleveland, Ohio • Houston, Texas
Conditions
Gout
Interventions
Rilonacept, Placebo, Allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 71 more
Conditions
Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome, Trisomy 13, Trisomy 18, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
BillionToOne Inc.
Industry
Eligibility
Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Riverside, California • West Covina, California + 5 more
Conditions
Tardive Dyskinesia
Interventions
NBI-1065890, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
31
States / cities
Bryant, Arkansas • Chino, California • Fountain Valley, California + 27 more
Conditions
COVID-19
Interventions
Remdesivir (RDV), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Mesa, Arizona • Tucson, Arizona • Bakersfield, California + 20 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

NCT01369303
Conditions
Prevention
Interventions
Tenofovir 1% vaginal gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Conditions
Uterine Cancer, Cervical Cancer, Endometrial Cancer
Interventions
Intensity Modulated Radiotherapy (IMRT), CT Scan
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR b.i.d. (Twice Daily)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Birmingham, Alabama • Berkeley, California • Los Angeles, California + 22 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
80
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 73 more
Conditions
Leukemia, Myeloproliferative Diseases
Interventions
Clofarabine, Cytarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Biliary Tract Cancer
Interventions
Varlitinib, Capecitabine, Placebo (for Varlitinib)
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
Not listed
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Gilbert, Arizona • Detroit, Michigan • St Louis, Missouri + 8 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide J, Semaglutide B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
55
States / cities
Gilbert, Arizona • Costa Mesa, California • La Mesa, California + 45 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
47
States / cities
Escondido, California • Fresno, California • Greenbrae, California + 42 more
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
29
States / cities
Birmingham, Alabama • Duarte, California • Oxnard, California + 24 more
Conditions
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Albany, New York • Houston, Texas
Conditions
Obsessive-Compulsive Disorder
Interventions
Troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
73
States / cities
Chandler, Arizona • Phoenix, Arizona • Bellflower, California + 62 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208
Conditions
RSV
Interventions
RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
Conditions
Osteoarthritis of the Knee
Interventions
1.2% Sodium Hyaluronate, Buffered Saline
Device
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
34
States / cities
Homewood, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 30 more
Active, not recruiting Phase 1Phase 2 Interventional

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

NCT06260774
Conditions
Advanced Solid Tumor
Interventions
TTX-MC138
Drug
Lead sponsor
TransCode Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • West Valley City, Utah + 1 more